AstraZeneca buys Ardea for US$1.26bn

AstraZeneca is to acquire Ardea, a San Diego, California-based biotechnology company focused on gout drugs, firing a wave of M&A in the biotechnology sector. Ardea’s clinically most advanced product candidate, lesinurad (formerly…